Adjunct Terbinafine in Patients With Leukemia and Invasive Fusariosis With Skin Lesions: Discordance Between Responses of Skin Lesions and Systemic Outcomes.

This article examines the use of adjunct terbinafine (TRB) in patients with leukemia and invasive fusariosis (IF) with skin lesions. IF is a severe mold infection that often has poor outcomes, particularly in patients with blood cancers. The study reviewed adult leukemia patients with documented IF and found that while some patients saw improvement or stabilization of their skin lesions with TRB treatment, there were poor overall outcomes and progression of IF in other areas of the body. The majority of patients died within 42 days of starting TRB. The article includes a table summarizing the characteristics and outcomes of 14 patients with blood cancer who were diagnosed with IF and treated with oral TRB in combination with other therapies. The document also discusses the limitations of oral TRB and raises concerns about its effectiveness in treating systemic IF. The authors note that the use of TRB for disseminated IF in blood cancer patients is limited and that a drug's effectiveness depends on its behavior in the body. The article concludes by disclosing potential conflicts of interest and providing contact information for further inquiries. [Extracted from the article]